Source recordFED

Laurent Pharmaceuticals Inc.

Federal grants & contributions· Industrial Research Assistance Program – Contributions to Firms· National Research Council Canada· FY2023· $7,000,000· BN 835517442· QC

Description

The project is focusing on Phase 3 pivotal study of LAU-7b in moderate-to-severe hospitalized COVID-19 patients, and has a component allowing the transition to a new Phase 2 clinical development in mild-to-moderate non-hospitalized COVID-19…

Amendment chain · 3 entries

Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $7,000,000 at start, $7,000,000 after amendment #3 (+$0).

$7,000,000$0Original · 2023-02-01 (start date) · total $7,000,000Amendment 2 · 2024-03-11 · total $7,000,000Amendment 3 · 2024-12-03 · total $7,000,000
  • #02023-02-01$7,000,000
  • #22024-03-11$7,000,000
  • #32024-12-03$7,000,000
RowDateTotal value as of rowChange vs previousDescription on this row
#0 original2023-02-01(start date)$7,000,000—The project is focusing on Phase 3 pivotal study of LAU-7b in moderate-to-severe hospitalized COVID-19 patient…
#2 amendment2024-03-11$7,000,000+$0The project is focusing on Phase 3 pivotal study of LAU-7b in moderate-to-severe hospitalized COVID-19 patient…
#3 amendment2024-12-03$7,000,000+$0The project is focusing on Phase 3 pivotal study of LAU-7b in moderate-to-severe hospitalized COVID-19 patient…

Related records · 10

Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).

Other current agreements for the same recipient (business number 835517442)

RefDepartment · programCurrent valueFY
172-2020-2021-Q4-967293National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program$21,676FY2021
172-2020-2021-Q3-958708National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms$10,000,000FY2021
172-2020-2021-Q3-960877National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program$48,704FY2021
172-2020-2021-Q1-949490National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program$40,656FY2021
172-2019-2020-Q3-939069National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms$665,000FY2020

Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)

RefRecipientFiscal yearCurrent valueFY
172-2025-2026-Q2-1034675Mediphage Bioceuticals, Inc.FY2027$63,380FY2027
172-2025-2026-Q3-1037522OBKIO INC.FY2026$50,000FY2026
172-2025-2026-Q3-1037889SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INCFY2026$25,000FY2026
172-2025-2026-Q2-1034040Griffith Foods LimitedFY2026$54,880FY2026
172-2025-2026-Q3-1037273Apollo Machine & Welding Ltd.FY2026$230,000FY2026

Cite as: Glassbox record view · Federal grants & contributions · 172-2022-2023-Q4-1002706 · retrieved 2026-11-16.